Varex Hit With Two Merger Suits and 13 Demand Letters Days Before $18.90/Share Vote

summarizeSummary

Varex disclosed two stockholder lawsuits and 13 demand letters over the Teledyne merger proxy and voluntarily added supplemental disclosures, while confirming the $18.90 per share cash deal and the October 28, 2026 special meeting are unchanged.

check_boxKey Events · M&A and Partnerships · VREX

• Two Merger Suits Filed

  Stevens v. Varex (October 6, 2026) and Clark v. Varex (October 7, 2026), both in New York Supreme Court, allege the definitive proxy is misleading and seek to enjoin the merger or win rescission and damages.

• 13 Demand Letters Received

  Purported stockholders sent 13 demand letters, one including a draft complaint, demanding corrective disclosures; Varex denies the claims have merit.

• Proxy Voluntarily Supplemented

  To avoid delay risk, Varex added supplemental disclosures without admitting liability; the $18.90 per share cash consideration and October 28, 2026 special meeting timing are unchanged.

• Regulatory Calendar Updated

  The HSR waiting period expires 11:59 pm Eastern on November 19, 2026, and the UK NSIA review accepted October 8, 2026 runs until November 18, 2026.

auto_awesomeAnalysis · VREX · Manufacturing

With the special meeting only six days away, Varex opted to supplement its proxy rather than absorb the delay risk from two stockholder suits and 13 demand letters alleging the definitive proxy omitted information. Management calls the claims meritless, and neither the $18.90 per share cash consideration nor the meeting timing has changed, so the deal economics remain intact. Still, litigation seeking to enjoin the merger adds closing risk to a stock trading at $18.42 against an $18.90 deal price. The filing also fixes the remaining regulatory calendar: HSR expires November 19, 2026, and the UK NSIA review runs to November 18, 2026.